Psychological stress and cardiovascular diseases: clinical case

In the modern world, stress occupies a leading place among significant problems for humanity, being an etiological factor of about 80% of diseases. Social, physical and psychological factors can act as stressors that influence and determine the non-specific response of the body. In most cases, the nonspecific stress-induced reaction of the body is manifested by the picture of psychovegetative syndrome, an important component of which is the activation of the sympathetic nervous system. In a prolonged stress situation, psychovegetative syndrome can be a manifestation of stress-induced anxiety. Anxiety is detected in more than 25% of patients with a general somatic profile. Stress-induced reactions and anxiety can subsequently contribute to the development of psychogenic somatic pathology, including the cardiovascular pathology. Acute or chronic stress situation increases the risks of developing arterial hypertension, coronary heart disease, heart rhythm disorders. In the presence of background cardiac pathology, stress-induced reactions contribute to the deterioration of its course and reduce the effectiveness of treatment. The above indicates the need for a comprehensive assessment of the condition of patients with a general somatic profile. The active use in practical medicine of psychometric and psychodiagnostic scales for anxiety and depression is shown to assess the mental status of patients. When detecting stress-induced reactions or comorbid psychopathology, inclusion of psychotropic drugs, including antipsychotics (alimemazine), is indicated in the complex therapy. Timely administration of alimemazine in patients with a general somatic profile stops psychovegetative manifestations, has positive somatotropic effects due to the multimodal mechanism of action of the drug. In this clinical case, the use of alimemazine in a patient with hypertension, rhythm disorders and comorbid anxiety is presented.

1. Vancheri F., Longo G., Vancheri E., Henein M.Y. Mental Stress and Cardiovascular Health–Part I. J Clin Med. 2022;11(12):3353. https://doi.org/10.3390/jcm1112335.

2. Steptoe A., Kivimäki M. Stress and cardiovascular disease: an update on current knowledge. Annu Rev Public Health. 2013;(34):337–354. https://doi.org/10.1146/annurev-publhealth-031912-114452.

3. Everson-Rose S.A., Lewis T.T. Psychosocial factors and cardiovascular diseases. Annu Rev Public Health. 2005;(26):469–500. https://doi.org/0.1146/annurev.publhealth.26.021304.144542.

4. Cohen S., Tyrrell D.A., Smith A.P. Psychological stress and susceptibility to the common cold. N Engl J Med. 1991;325(9):606–612. https://doi.org/0.1056/NEJM199108293250903.

5. Goldberger J.J., Arora R., Buckley U., Shivkumar K. Autonomic Nervous System Dysfunction: JACC Focus Seminar. J Am Coll Cardiol. 2019;73(10):1189–1206. https://doi.org/10.1016/j.jacc.2018.12.064.

6. Brotman D.J., Golden S.H., Wittstein I.S. The cardiovascular toll of stress. Lancet. 2007;370(9592):1089–1100. https://doi.org/10.1016/S0140-6736(07)61305-1.

7. Everson-Rose S.A., Lewis T.T. Psychosocial factors and cardiovascular diseases. Annu Rev Public Health. 2005;26:469–500. https://doi.org/0.1146/annurev.publhealth.26.021304.144542.

8. Poitras V.J., Pyke K.E. The impact of acute mental stress on vascular endothelial function: evidence, mechanisms and importance. Int J Psychophysiol. 2013;88(2):124–135. https://doi.org/10.1016/j.ijpsycho.2013.03.019.

9. Hemingway H., Malik M., Marmot M. Social and psychosocial influences on sudden cardiac death, ventricular arrhythmia and cardiac autonomic function. Eur Heart J. 2001;22(13):1082–1101. https://doi.org/10.1053/euhj.2000.2534.

10. Batelaan N.M., Seldenrijk A., van den Heuvel O.A., van Balkom A.J.L.M., Kaiser A., Reneman L., Tan H.L. Anxiety, Mental Stress, and Sudden Cardiac Arrest: Epidemiology, Possible Mechanisms and Future Research. Front Psychiatry. 2022;(12):813518. https://doi.org/10.3389/fpsyt.2021.813518.

11. Lampert R. Mental Stress and Ventricular Arrhythmias. Curr Cardiol Rep. 2016;18(12):118. https://doi.org/10.1007/s11886-016-0798-6.

12. Henein M.Y., Vancheri S., Longo G., Vancheri F. The Impact of Mental Stress on Cardiovascular Health-Part II. J Clin Med. 2022;11(15):4405. https://doi.org/10.3390/jcm11154405.

13. Choi E.K., Shen M.J., Han S., Kim D., Hwang S., Sayfo S. et al. Intrinsic cardiac nerve activity and paroxysmal atrial tachyarrhythmia in ambulatory dogs. Circulation. 2010;121(24):2615–2623. https://doi.org/10.1161/CIRCULATIONAHA.109.919829.

14. Qu Z., Xie L.H., Olcese R., Karagueuzian H.S., Chen P.S., Garfinkel A., Weiss J.N. Early afterdepolarizations in cardiac myocytes: beyond reduced repolarization reserve. Cardiovasc Res. 2013;99(1):6–15. https://doi.org/10.1093/cvr/cvt104.

15. Franciosi S., Perry F.K.G., Roston T.M., Armstrong K.R., Claydon V.E., Sanatani S. The role of the autonomic nervous system in arrhythmias and sudden cardiac death. Auton Neurosci. 2017;(205):1–11. https://doi.org/10.1016/j.autneu.2017.03.005.

16. Shen M.J., Choi E.K, Tan A.Y., Lin S.F., Fishbein M.C., Chen L.S., Chen P.S. Neural mechanisms of atrial arrhythmias. Nat Rev Cardiol. 2011;9(1):30–39. https://doi.org/10.1038/nrcardio.2011.139.

17. Tan A.Y., Zhou S., Ogawa M., Song J., Chu M., Li H. et al Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. Circulation. 2008;118(9):916–925. https://doi.org/10.1161/CIRCULATIONAHA.108.776203.

18. Steptoe A., Kivimäki M. Stress and cardiovascular disease. Nat Rev Cardiol. 2012;9(6):360–370. https://doi.org/10.1038/nrcardio.2012.45.

19. Aleksandrova M.R., Lukashenko A.A., Yurovskaya I.I., Artem’ieva M.S. The role of emotional stress in the genesis of life-hreatening heart rhythm disorders. RUDN Journal of Medicine. 2014;(2):35–41. (In Russ.) Available at: https://cyberleninka.ru/article/n/rol-psihoemotsionalnogo-stressa-v-geneze-zhizneugrozhayuschih-narusheniy-ritma-serdtsa.

20. Bransfiel R.C., Friedman K.J. Differentiating Psychosomatic, Somatopsychic, Multisystem Illnesses and Medical Uncertainty. Healthcare. 2019;7(4):114. https://doi.org/10.3390/healthcare7040114.

21. Vasil’eva A.V. Actual problems of diagnosis of depressive disorders. Lechaschi Vrach. 2020. (In Russ.) Available at: https://www.lvrach.ru/partners/velaxin/15437705.

22. Akarachkova E.S. Revisiting the diagnosis and treatment of psychovegetative disorders in general somatic practice. Lechaschi Vrach. 2010;10:5–8. (In Russ.) Available at: https://www.lvrach.ru/2010/10/15435059.

23. Aleshina N.V. Use of the drug “Teralidgen” in the structure pharmacotherapy of infantile autism (procedural and organic). Psikhicheskoe Zdorov’e. 2014;2(93):70–72. (In Russ.) Available at: https://medi.ru/info/12312/.

24. Barantsevich E.R., Golovkova M.S., Dzhulaj I.A., Posokhina O.V., Starikov P.V. The efficacy and safety of teraligen in patients with brain ischemia, stages I and II, and psychoautonomic syndrome. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2015;12(115):86–91. (In Russ.) https://doi.org/10.17116/jnevro201511511286-91.

25. Medvedev V.E. Alimemazine in psychiatry and psychosomatic. Psikhiatriya i Psikhofarmakoterapiya. 2018;20(3–4):26–33. (In Russ.) Available at: https://con-med.ru/magazines/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina-03-04-2018/alimemazin_v_psikhiatrii_i_psikhosomatike.

26. Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma F.J. Jr., Shen Y. et al. Binding of typical and atypical antipsychotic agents to 5-hydroxy-tryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994;268(3):1403–1410. Available at: https://go.drugbank.com/articles/A4966.

27. Glusa E., Pertz H.H. Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br J Pharmacol. 2000;130(3):692–698. https://doi.org/10.1038/sj.bjp.0703341.

28. Germain A., Kupfer D.J. Circadian rhythm disturbances in depression. Hum Psychopharmacol. 2008;23(7):571–585. https://doi.org/10.1002/hup.964.

29. Poluektov M.G. Sleep disorders in childhood: causes and modern therapy. Effective Pharmacotherapy. 2012;(1):32–39. (In Russ.) Available at: https://con-med.ru/upload/iblock/af8/poluektov-mg-narusheniya-sna-v-detskom-vozraste-effektivnaya-farmakoterapiya-nip-01-2012.pdf.

30. Reshetova T.V. Many faces of hysteria in general medical practice. Atmosfera: Nervnye Bolezni. 2008;(3):13–14. (In Russ.) Available at: https://con-med.ru/upload/iblock/6c2/reshetova-tv-mnogolikaya-isteriya-v-obshchey-vrachebnoy-praktike-atmosfera.-nervnye-bolezni-03-2008.pdf.

31. Reshetova T.V. Autonomic nervous system disorders and treatment in general medical practice. Atmosfera: Nervnye Bolezni. 2008;(4):6–8. (In Russ.) Available at: https://cyberleninka.ru/article/n/narusheniya-vegetativnoy-nervnoy-sistemy-v-obschey-vrachebnoy-praktike-i-ih-lechenie.

32. Menzel M. Experience with theralene (alimemazine) in internal medicine. Med klin. 1964;(59):1438–1440. Available at: https://pubmed.ncbi.nlm.nih.gov/14315271.

33. Votchal B.E. Essays on Clinical Pharmacology. 2nd ed. Moscow: Meditsina; 1965. 491 p. (In Russ.)

34. Raginene I.G., Akhapkin F.A. Somnological and Vegetative Disorders in Patients with Neurological Profile and Acute Vascular Pathology. Effective Pharmacotherapy. 2014;5(49):4–7. (In Russ.) Available at: https://umedp.ru/articles/somnologicheskie_i_vegetativnye_narusheniya_u_bolnykh_nevrologicheskogo_profilya_s_ostroy_sosudistoy. html?sphrase_id=99066.

35. Shmilovich A.A., Goncharenko S.N. Efficacy and safety studies review of Teraligen usage in psychiatric practice and general medicine. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2022;122(6):55–62. (In Russ.) https://doi.org/10.17116/jnevro202212206155.

36. Edin A.S. To the question of the use of alimamazine (Teraligen®) in patients with atopic dermatitis in combination with anxiety-depressive disorder. Consilium Medicum. 2018;20(2):145–150. (In Russ.) https://doi.org/10.26442/2075-1753_2018.2.145-150.